Form D · Pharmaceuticals
Clade Therapeutics, Inc.
Cambridge, MA · CIK 0001893119
Offering snapshot reported Jan 3, 2022 · SEC filing
- Reported sold
- $42K Offering amount: $66K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 17, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 3, 2022 | Initial | $42,000 | No comparison | 1 | SEC filing |
| Nov 12, 2021 | Initial | $45,892,093 | No comparison | 31 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-427506
Shares issued as partial consideration for rights granted to Issuer under certain license agreement.
Source: Form D, filed Jan 3, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Chad A. Cowan | Director, Executive |
| Jim Glasheen | Director, Executive |
| Martin Murphy | Director |
| Daniel Vasella | Director |
| Leandro Vetcher | Executive |
| Neil White | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1 Kendall Square, Suite B200
Cambridge, MA, 02139
Cambridge, MA, 02139